


Supplementary Material

Interstitial Photodynamic Therapy using 5-ALA for Malignant Glioma Recurrences


Stefanie Lietke, Michael Schmutzer, Christoph Schwartz, Jonathan Weller, Sebastian Siller, Maximilian Aumiller, Christian Heckl, Robert Forbrig, Maximilian Niyazi, Rupert Egensperger, Herbert Stepp, Ronald Sroka, Jörg C. Tonn, Adrian Rühm and Niklas Thon

Supplementary Table S1. Prognostic factors for TTF after iPDT in uni- and multivariate models HR - Hazard ratio, CI – confidence interval.

Characteristic	Univariate			Multivariate		
	HR	95% CI	P-value	HR	95% CI	P-value
Time to treatment failure (after iPDT)						
Age at iPDT	1.001	.977-1.026	.910	1.035	.978-1.094	.236
KPS at iPDT	.973	.940-1.007	.121	.970	.925-1.018	.222
MGMT methylation	.856	.446-1.641	.639	1.221	.386-3.860	.734
IDH mutation	.849	.393-1.835	.677	1.244	.380-4.076	.718
Target volume	1.000	.934-1.071	.998	1.001	.926-1.083	.974
Time to iPDT	1.006	.999-1.013	.118	1.005	.995-1.016	.328
Further Chemotherapy	1.366	.708-2.638	.352	1.023	.439-2.387	.958
Further Radiotherapy	.999	.536-1.860	.997	.662	.205-2.137	.490
Further Surgery	1.131	.400-3.196	.817	1.724	.374-7.950	.485



(a)



(b)

Supplementary figure S1. Survival curves. (a) Time-to-treatment failure (TTF) of the intention to treat population after iPDT treatment; (b) post-recurrence survival (PRS) of the intention to treat population after iPDT treatment.